Rundu Co., Ltd.
润都股份
002923
Shenzhen Stock Exchange
Key Financials
As of 2026-05-16T00:00:00.000+00:00Announcements
Announcement on Pledge of Shares by Company's Controlling Shareholder and Joint Actual Controllers
Announcement on Obtaining Drug Registration Certificate for Diclofenac Sodium Sustained-Release Tablets
Announcement on Obtaining the Approval Notice for the Listing Application of Telmisartan Chemical Raw Materials
Announcement on Holding the 2025 Performance Briefing
Announcement on the pre-disclosure of share reduction by shareholders holding more than 5%
Announcement on receiving the approval notice for the listing application of losartan potassium chemical raw materials.
Announcement on the Reappointment of the Accounting Firm
2025 Independent Director Work Report (Wang Bo)
2025 Independent Director Work Report (Hu Zhengxi)
2025 Independent Director Work Report (TANWEN)
2025 Independent Director Work Report (Ye Jianmu)
2025 Environmental, Social, and Governance (ESG) Report
2025 Annual Internal Control Audit Report
2025 Annual Internal Control Self-Evaluation Report
Announcement on the Provision for Credit Impairment Losses and Asset Impairment Losses for 2025
Notice of the 2025 Annual Shareholders' Meeting
2026 Annual Compensation Plan for Directors and Senior Management
2025 Annual Board Work Report
Announcement of the Resolutions from the Third Meeting of the Sixth Board
Announcement on the Proposal Not to Distribute Profits for 2025
2026 First Quarter Report
Board's Special Explanation on the Securities Investment Situation for 2025
Special Verification Report on the Deduction of Operating Income for 2025
Evaluation Report on the Accounting Firm's Performance in 2025
Report from the Board Audit Committee on the Evaluation of the Accounting Firm's Performance in 2025 and Supervision Responsibilities
Special Audit Report on the Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions
Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025
Board's Special Opinion on the Independence of Independent Directors
2025 Annual Audit Report
2025 Annual Report
Summary of the 2025 Annual Report
Announcement on the Approval Notice for the Listing Application of Chemical Raw Material Drug for Hydrochloride De-Nor-Scopolamine
Notes & Comments
Sign in to leave a comment or private note.
Loading…